We are revolutionizing the translational potential of animal models in preclinical research. Discover the latest articles and news about our recent activities.
8 June 2022
PhoenixBio is thrilled to be attending EASL's International Liver Congress in person at the ExCeL in London, UK on June 22nd - 26th, 2022. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance future therapies for HBV, HDV/HBV, HCV, NASH/NAFLD, Gene Editing, Gene Therapy, Drug Metabolism, Pharmacokinetics, and Toxicology.
12 May 2022
PhoenixBio is delighted to be attending ASGCT in person at the Walter E. Washington Convention Center in Washington, DC on May 16 - 19, 2022. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.
3 January 2022
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries, with an estimated incidence of around 25% worldwide.
9 August 2021
As the liver is the primary site for drug metabolism, the PXB-mouse is the best available model to predict human-specific metabolism prior to clinical trials. Two Studies performed with the support of PhoenixBio through the Chimeric Mouse with Humanized Liver (CMHL) Consortium are highlighted below.
1 April 2021
PhoenixBio Co., Ltd. (“PhoenixBio”) announced today that it has entered into an agreement to partner with Inotiv, Inc. (“Inotiv”) in providing pre-clinical research services utilizing the PXB-mouse® (cDNA-uPA/SCID mouse model with a humanized liver).
1 March 2021
PhoenixBio is pleased to be participating in the 2021 Society of Toxicology Annual Meeting.
1 February 2021
Rare Disease Day takes place on the last day of February each year since 2008. The main objective of Rare Disease Day is to raise awareness about rare diseases and the impact they have on lives.
